Nobody dares stopping clinical research, not even COVID-19

Benzer Materyaller

• The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
  Yazar:: Miguel Sampayo-Cordero, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-09-01)
• The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
  Yazar:: Sampayo-Cordero, Miguel, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”
  Yazar:: Sampayo-Cordero, Miguel, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
  Yazar:: Di Cosimo, Serena, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
  Yazar:: Sampayo-Cordero, Miguel, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)